1. Home
  2. SRL vs PYPD Comparison

SRL vs PYPD Comparison

Compare SRL & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scully Royalty Ltd.

SRL

Scully Royalty Ltd.

N/A

Current Price

$8.61

Market Cap

83.0M

ML Signal

N/A

Logo PolyPid Ltd.

PYPD

PolyPid Ltd.

N/A

Current Price

$4.17

Market Cap

77.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SRL
PYPD
Founded
2017
2008
Country
China
Israel
Employees
N/A
N/A
Industry
Professional Services
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.0M
77.4M
IPO Year
1996
2014

Fundamental Metrics

Financial Performance
Metric
SRL
PYPD
Price
$8.61
$4.17
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$12.00
AVG Volume (30 Days)
27.0K
39.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
11.71%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.13
$2.30
52 Week High
$10.39
$5.12

Technical Indicators

Market Signals
Indicator
SRL
PYPD
Relative Strength Index (RSI) 46.11 43.67
Support Level $8.66 $4.01
Resistance Level $9.60 $4.38
Average True Range (ATR) 0.29 0.18
MACD -0.08 0.00
Stochastic Oscillator 30.00 41.86

Price Performance

Historical Comparison
SRL
PYPD

About SRL Scully Royalty Ltd.

Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.

About PYPD PolyPid Ltd.

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.

Share on Social Networks: